CY6463

DRUG2 trials

Sponsors

Tisento Therapeutics

Conditions

Alzheimer's Disease With Vascular PathologySchizophrenia

Phase 1

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

CompletedNCT04972227

Tisento TherapeuticsSchizophrenia

Start: 2021-09-10End: 2022-04-18Updated: 2024-08-13

Phase 2

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

TerminatedNCT04798989

Tisento TherapeuticsAlzheimer's Disease With Vascular Pathology

Start: 2021-11-02End: 2022-11-28Updated: 2024-10-30